** Stock on track for its best session since December 3, 2025, if gains hold
** Stock saps a four-session losing streak, and last up 3.6%
** The pharmaceutical co signs a second cooperative research and development agreement with the U.S. Army Institute of Surgical Research
** Agreement to conduct study to evaluate effectiveness of RECCE 327 gel in reducing bioburden burn wounds
** Stock is down 10.8%, YTD
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.